Literature DB >> 21322019

Clinical subtypes of Parkinson's disease.

Stephanie M van Rooden1, Fabrice Colas, Pablo Martínez-Martín, Martine Visser, Dagmar Verbaan, Johan Marinus, Ray K Chaudhuri, Joost N Kok, Jacobus J van Hilten.   

Abstract

The clinical heterogeneity of Parkinson's disease (PD) may point at the existence of subtypes. Because subtypes likely reflect distinct underlying etiologies, their identification may facilitate future genetic and pharmacotherapeutic studies. Aim of this study was to identify subtypes by a data-driven approach applied to a broad spectrum of motor and nonmotor features of PD. Data of motor and nonmotor PD symptoms were collected in 802 patients in two different European prevalent cohorts. A model-based cluster analysis was conducted on baseline data of 344 patients of a Dutch cohort (PROPARK). Reproducibility of these results was tested in data of the second annual assessment of the same cohort and validated in an independent Spanish cohort (ELEP) of 357 patients. The subtypes were subsequently characterized on clinical and demographic variables. Four similar PD subtypes were identified in two different populations and are largely characterized by differences in the severity of nondopaminergic features and motor complications: Subtype 1 was mildly affected in all domains, Subtype 2 was predominantly characterized by severe motor complications, Subtype 3 was affected mainly on nondopaminergic domains without prominent motor complications, while Subtype 4 was severely affected on all domains. The subtypes had largely similar mean disease durations (nonsignificant differences between three clusters) but showed considerable differences with respect to their association with demographic and clinical variables. In prevalent disease, PD subtypes are largely characterized by the severity of nondopaminergic features and motor complications and likely reflect complex interactions between disease mechanisms, treatment, aging, and gender.
Copyright © 2010 Movement Disorder Society.

Entities:  

Mesh:

Year:  2010        PMID: 21322019     DOI: 10.1002/mds.23346

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  65 in total

1.  Defining a comprehensive verotype using electronic health records for personalized medicine.

Authors:  Mary Regina Boland; George Hripcsak; Yufeng Shen; Wendy K Chung; Chunhua Weng
Journal:  J Am Med Inform Assoc       Date:  2013-09-03       Impact factor: 4.497

2.  Disease progression in Parkinson subtypes: the PPMI dataset.

Authors:  Darko Aleksovski; Dragana Miljkovic; Daniele Bravi; Angelo Antonini
Journal:  Neurol Sci       Date:  2018-08-14       Impact factor: 3.307

Review 3.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

4.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

Review 5.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

6.  Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.

Authors:  Eduardo De Pablo-Fernandez; Carmen Tur; Tamas Revesz; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

7.  Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.

Authors:  Eduardo De Pablo-Fernández; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

Review 8.  Different diagnostic criteria for Parkinson disease: what are the pitfalls?

Authors:  Roongroj Bhidayasiri; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-15       Impact factor: 3.575

Review 9.  Neural and immune mechanisms in the pathogenesis of Parkinson's disease.

Authors:  Fabio Blandini
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-03       Impact factor: 4.147

10.  Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism.

Authors:  Samay Jain; Seo-Young Park; Diane Comer
Journal:  Neuroepidemiology       Date:  2015-07-30       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.